Liproxstatin-1: Potent Ferroptosis Inhibitor with IC50 22 nM for Ferroptosis Research

Executive Summary: Liproxstatin-1 (SKU B4987, APExBIO) is a selective ferroptosis inhibitor with a nanomolar IC50 of 22 nM, blocking lipid peroxidation and protecting GPX4-deficient cells (product data). It is insoluble in water but dissolves in DMSO (≥10.5 mg/mL) and ethanol (≥2.39 mg/mL) with warming and sonication, and requires -20°C storage for stability. Liproxstatin-1 prolongs survival in renal failure models and reduces tissue damage in hepatic ischemia/reperfusion injury (Yu et al., 2026). Its validated role in ferroptosis research enables precise modulation of the iron-dependent cell death pathway. The compound is widely adopted in cell viability, cytotoxicity, and translational organ injury studies (see related review).

Biological Rationale

Ferroptosis is a regulated cell death pathway distinct from apoptosis and necrosis. It is characterized by iron dependency and excessive lipid peroxidation in cell membranes (Yu et al., 2026). Glutathione peroxidase 4 (GPX4) is a key enzyme that detoxifies lipid hydroperoxides; its deficiency or inhibition sensitizes cells to ferroptosis. Liproxstatin-1 specifically targets this pathway by blocking lipid peroxide accumulation, thus protecting cells from ferroptotic death. The compound is instrumental in studying oxidative stress, iron overload, and the intersection of metal-dependent cell death pathways such as cuproptosis and ferroptosis.

Mechanism of Action of Liproxstatin-1

Liproxstatin-1 acts as a potent, selective inhibitor of ferroptosis. Mechanistically, it prevents the formation and propagation of lipid peroxides—a hallmark of ferroptosis—by intercepting free radicals and inhibiting chain reactions in polyunsaturated fatty acid (PUFA)-rich phospholipids (APExBIO, product page). Liproxstatin-1 is particularly effective in cellular models lacking functional GPX4, a critical antioxidant enzyme. The compound does not block other forms of cell death, such as apoptosis or necroptosis, underscoring its pathway specificity. Its inhibition of lipid peroxidation is quantifiable via malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE) assays, and protective effects have been validated in multiple organ systems. Recent reviews confirm that Liproxstatin-1 does not affect upstream iron import or glutathione synthesis but acts downstream to halt lethal peroxidation events (see mechanistic analysis).

Evidence & Benchmarks

• Liproxstatin-1 inhibits ferroptosis with an IC50 of 22 nM in cell-based assays using GPX4-deficient murine embryonic fibroblasts (MEFs) (APExBIO).
• The compound prevents RSL3-induced lipid peroxidation in viable cells, as measured by BODIPY-C11 fluorescence (Yu et al., 2026, Table S2).
• Liproxstatin-1 administration in conditional Gpx4 knockout mice (10 mg/kg, intraperitoneal, daily) significantly prolongs survival in renal failure models (Yu et al., 2026, Figure 3).
• In hepatic ischemia/reperfusion injury, Liproxstatin-1 reduces MDA levels and tissue necrosis, supporting its translational potential (see organ injury review).
• The compound remains inactive in apoptosis or cuproptosis models, confirming specificity for the ferroptotic pathway (Yu et al., 2026).

Applications, Limits & Misconceptions

Liproxstatin-1 is a research tool for dissecting ferroptosis in cancer, neurodegeneration, and organ injury. It is widely used in cell viability and cytotoxicity assays, especially where GPX4 inhibition or iron overload is present. The compound provides a benchmark for evaluating novel ferroptosis inducers or antagonists. In vivo, its protective effects have been demonstrated in kidneys and liver injury models. However, Liproxstatin-1 is not effective against cell death pathways unrelated to lipid peroxidation or iron metabolism. It does not substitute for genetic models of ferroptosis and should not be used as a therapeutic agent in humans.

This article extends the scope of "Liproxstatin-1 (SKU B4987): Advancing Ferroptosis Inhibit..." by integrating recent evidence on in vivo efficacy and workflow parameters under standardized protocols. It also clarifies mechanistic boundaries compared to "Ferroptosis Inhibition as a Strategic Lever: Mechanistic ...", which focuses primarily on pathway-level theory.

Common Pitfalls or Misconceptions

• Not a pan-cell death inhibitor: Liproxstatin-1 does not inhibit apoptosis, necroptosis, or cuproptosis.
• Solubility constraints: The compound is insoluble in water; improper solvent use may result in precipitation and loss of activity.
• Short-term stability: Solutions in DMSO or ethanol must be used promptly; storage at -20°C is critical for powder stability.
• No therapeutic approval: Liproxstatin-1 is strictly for laboratory research and is not approved for clinical use.
• Not a direct iron chelator: The compound blocks lipid peroxidation but does not alter cellular iron homeostasis directly.

Workflow Integration & Parameters

For cell-based assays, Liproxstatin-1 is typically dissolved at 10 mM in DMSO and diluted to final working concentrations (10–500 nM) in culture media (APExBIO). For animal studies, intraperitoneal dosing at 10 mg/kg is standard in murine models, with efficacy seen in both acute and chronic injury paradigms. Researchers should ensure the absence of water in solvent systems to prevent precipitation. Storage at -20°C as a dry powder is recommended; aliquoted solutions in DMSO are stable for short-term use (≤1 week). Endpoint readouts include cell viability (MTT, CCK-8), lipid peroxidation (BODIPY-C11, MDA), and organ function markers in vivo. For further workflow guidance, see "Liproxstatin-1 (SKU B4987): Data-Driven Solutions for Rel...", which provides troubleshooting tips and real-world case studies.

Conclusion & Outlook

Liproxstatin-1 (APExBIO, B4987) is a gold-standard reagent for dissecting ferroptosis in diverse models. Its nanomolar potency, pathway selectivity, and in vivo efficacy have been validated in peer-reviewed studies (Yu et al., 2026). The compound enables high-confidence, mechanistically precise studies of iron-dependent lipid peroxidation and organ injury. Future directions include combinatorial screens with other metal homeostasis modulators and refinement of dosing protocols for translational research. For detailed specifications and ordering, reference the Liproxstatin-1 product page.